Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q3 2023
Holdings as of Sep 30, 2023, filed Nov 14, 2023. Long positions only; changes compare share counts with Q2 2023.
- Positions
- 39
- +3 vs. Q2 2023
- Portfolio value
- $531.6M
- +$32.4M (+6.5%) vs. Q2 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| URGNUroGen Pharma Ltd. | COM | 2,620,545 | $36.7M | 6.9% | +2,620,545 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 3,078,633 | $35.3M | 6.6% | −285,055−8.5% | Reduced | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,755,184 | $30.4M | 5.7% | +205,000+13.2% | Added | History |
| PCVXVaxcyte, Inc. | COM | 531,211 | $27.1M | 5.1% | −58,000−9.8% | Reduced | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 727,426 | $25.9M | 4.9% | +50,000+7.4% | Added | History |
| ALKSAlkermes plc. | SHS | 875,044 | $24.5M | 4.6% | +463,591+112.7% | Added | History |
| RAPTRAPT Therapeutics, Inc. | COM | 1,458,070 | $24.2M | 4.6% | −7,081−0.5% | Reduced | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 3,295,000 | $21.7M | 4.1% | 00.0% | Unchanged | History |
| SRPTSarepta Therapeutics, Inc. | COM | 165,200 | $20.0M | 3.8% | +41,600+33.7% | Added | History |
| EOLSEvolus, Inc. | COM | 2,186,934 | $20.0M | 3.8% | −247,114−10.2% | Reduced | History |
| PNTPOINT Biopharma Global Inc. | COM | 2,909,960 | $19.4M | 3.7% | −90,040−3.0% | Reduced | History |
| CYTKCytokinetics Inc | COM NEW | 600,000 | $17.7M | 3.3% | 00.0% | Unchanged | History |
| XENEXenon Pharmaceuticals Inc. | COM | 500,001 | $17.1M | 3.2% | −29,999−5.7% | Reduced | History |
| ANABAnaptysbio, Inc | COM | 894,333 | $16.1M | 3.0% | 00.0% | Unchanged | History |
| IMCRImmunocore Holdings plc | ADS | 290,917 | $15.1M | 2.8% | −6,165−2.1% | Reduced | History |
| JBIOJade Biosciences, Inc. | COM | 1,091,233 | $14.8M | 2.8% | +159,075+17.1% | Added | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 225,000 | $11.7M | 2.2% | +225,000 | New | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,691,768 | $11.6M | 2.2% | −249,813−12.9% | Reduced | History |
| PTCTPTC Therapeutics, Inc. | COM | 500,000 | $11.2M | 2.1% | +500,000 | New | History |
| REPLReplimune Group, Inc. | COM | 638,495 | $10.9M | 2.1% | +638,495 | New | History |
| OPTNOptiNose, Inc. | COM | 8,839,939 | $10.9M | 2.0% | 00.0% | Unchanged | History |
| FOLDAmicus Therapeutics, Inc. | COM | 857,000 | $10.4M | 2.0% | +155,608+22.2% | Added | History |
| ACLXArcellx, Inc. | COMMON STOCK | 287,500 | $10.3M | 1.9% | +250,000+666.7% | Added | History |
| KRTXKaruna Therapeutics, Inc. | COM | 60,500 | $10.2M | 1.9% | +60,500 | New | History |
| AKROAkero Therapeutics, Inc. | COM | 198,500 | $10.0M | 1.9% | +198,500 | New | History |
| INSMINSMED Inc | COM PAR $.01 | 394,872 | $9.97M | 1.9% | +394,872 | New | History |
| OKUROnKure Therapeutics, Inc. | COM | 1,167,061 | $8.89M | 1.7% | +83,744+7.7% | Added | History |
| APGEApogee Therapeutics, Inc. | COM | 400,000 | $8.52M | 1.6% | +400,000 | New | History |
| GOSSGossamer Bio, Inc. | COM | 6,230,272 | $5.19M | 1.0% | +6,230,272 | New | History |
| IGMSIGM Biosciences, Inc. | COM | 615,317 | $5.14M | 1.0% | +115,317+23.1% | Added | History |
| HRTXHeron Therapeutics, Inc. | COM | 4,737,368 | $4.88M | 0.9% | 00.0% | Unchanged | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 215,000 | $4.69M | 0.9% | +215,000 | New | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 1,074,101 | $4.46M | 0.8% | +22,834+2.2% | Added | History |
| GBIOGeneration Bio Co. | COM | 1,022,537 | $3.88M | 0.7% | 00.0% | Unchanged | History |
| MRTXMirati Therapeutics, Inc. | COM | 86,302 | $3.76M | 0.7% | +86,302 | New | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 645,899 | $3.25M | 0.6% | +645,899 | New | History |
| TRMLTourmaline Bio, Inc. | COM | 1,000,000 | $2.81M | 0.5% | +333,967+50.1% | Added | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 579,667 | $1.67M | 0.3% | −1,688,390−74.4% | Reduced | – |
| SLDBSolid Biosciences Inc. | COM NEW | 450,403 | $1.14M | 0.2% | −134,055−22.9% | Reduced | History |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q2 2023 (9)
Positions held at the end of Q2 2023 that are gone from this filing.
| Security | Class | Shares in Q2 2023 | Value in Q2 2023 | % of portfolio in Q2 2023 | History |
|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 968,795 | $20.9M | 4.2% | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 772,000 | $12.7M | 2.6% | History |
| VKTXViking Therapeutics, Inc. | COM | 598,550 | $9.70M | 1.9% | History |
| MLYSMineralys Therapeutics, Inc. | COM | 546,059 | $9.31M | 1.9% | History |
| ICPTIntercept Pharmaceuticals, Inc. | COM | 601,322 | $6.65M | 1.3% | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 350,000 | $6.32M | 1.3% | History |
| MCRBSeres Therapeutics, Inc. | COM | 938,067 | $4.49M | 0.9% | History |
| DTILPrecision Biosciences Inc | COM | 7,469,736 | $3.93M | 0.8% | History |
| TVTXTravere Therapeutics, Inc. | COM | 60,000 | $921.6K | 0.2% | History |